

**CF FOUNDATION/NIH FUNDING AWARD**

*Purpose:* The Cystic Fibrosis Foundation has developed its research grant program to complement the granting mechanism of the National Institutes of Health (NIH). Support from the CF Foundation, through various mechanisms, is intended to provide for the development of sufficient preliminary data to make CF grant-related applications highly competitive in the NIH review process. However, as a result of funding constraints on the NIH, coupled with the growing interest in CF research, there are occasions in which highly meritorious grants are submitted to the NIH and may not be funded. In an effort to assure that all meritorious CF-related research is supported, the CF Foundation has developed a mechanism to provide for CF Foundation funding. The objective of this award is to support excellent CF-related research projects that have been submitted to and approved by the NIH, but cannot be supported by available NIH funds. Applications must fall within the upper 40th percentile with a priority score of 200 or better.

*Term/Amount:* CF Foundation support ranges from \$75,000 to \$125,000 per year for up to two years.

*Contact:* Please direct inquiries to: Office of Grants Management, Cystic Fibrosis Foundation, 6931 Arlington Road, Bethesda, MD 20814. Telephone: (800)-FIGHT-CF.

*Deadline:* On-going basis.

**HYPERACCELERATED AWARD/MECHANISMS IN IMMUNOMODULATION TRIALS: AI-00-005**

*Purpose:* The National Institute of Allergy and Infectious Diseases (NIAID), the National Institute on Aging (NIA), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Heart, Lung and Blood Institute (NHLBI), the National Institute of Neurological Disorders and Stroke (NINDS), and the Office of Research on Women's Health (ORWH) of the National Institutes of Health (NIH) invite investigator-initiated research applications for mechanistic studies in clinical trials of immunomodulatory interventions for immune system mediated diseases, including, but not limited to, asthma and allergy, graft failure in solid organ, tissue, cell, and stem cell transplantation, and autoimmune diseases. Specifically, this Request for Applications (RFA) is a continuation and modification of RFA AI-98-006. It focuses on the inclusion of patients and utilization of patient samples for the evaluation of immunologic and other relevant parameters to facilitate the study and definition of immunological mechanisms underlying the intervention, the mechanisms of disease pathogenesis, surrogate/biomarkers markers of disease activity and therapeutic effect, and mechanisms of human immu-

nologic function. The parent or core clinical trial must have independent financial support and will NOT receive support under this RFA. Proposed mechanistic studies associated with clinical trials supported by industry are particularly encouraged but clinical trials supported by any source, public or private, are eligible.

*Term/Amount:* The mechanism of support will be the individual research project grant (R01). The total requested project period for an application submitted in response to this RFA may not exceed four years. Some sponsoring Institutes may administratively limit the duration of award. Applicants for the R01 mechanism must not exceed a first-year limit of \$250,000 direct costs. Modular grant procedures should be used. Specific application instructions have been modified to reflect "Modular Grant" and "Just-in-Time" streamlining efforts being examined by the NIH. Complete and detailed instructions and information on Modular Grant applications can be found at <http://grants.nih.gov/grants/funding/modular/modular.htm>. The estimated total funds (direct and indirect costs) available for the first year of support for all awards made under this RFA in FY 2000 will be \$1,800,000. In Fiscal Year 1999, seven awards were made. The usual PHS policies governing grants administration and management will apply. Although this program is provided for in the financial plans of the participating institutes, awards pursuant to this RFA are contingent upon the availability of funds for this purpose and the receipt of a sufficient number of applications of high scientific merit. Funding beyond the first and subsequent years of the grant will be contingent upon satisfactory progress during the preceding years and availability of funds.

*Contact:* Applications are to be submitted on the grant application for PHS 398 (rev. 4/98). These forms are available at most institutional offices of sponsored research and may be obtained from the Division of Extramural Outreach and Information Resources, National Institutes of Health, 6701 Rockledge Drive, MSC 7910, Bethesda, MD 20892-7910. Telephone: (301) 435-0714; E-mail: [grantsinfo@nih.gov](mailto:grantsinfo@nih.gov) and on the Internet at <http://grants.nih.gov/grants/funding/phs398/phs398.html>; Web site: <http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-00-005.html>

*Deadline:* Letter of Intent Receipt Date: One month before application receipt date. Application Receipt Date: Applications will be accepted MONTHLY on the 9th of each month.

**SPECIALIZED CENTERS OF RESEARCH (SCORs) IN SYSTEMIC LUPUS ERYTHEMATOSUS AND IN OSTEOARTHRITIS: AR-01-005**

*Purpose:* The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) invites applications for Specialized Centers of Research (SCORs) in